Our collaborations provide access to additional knowledge, experience, expertise, and human and financial resources.
Contact Business Development regarding licensing or collaboration opportunities.
We are collaborating with Bayer Healthcare and Sanofi, two of the world’s leading global pharmaceutical companies, to bring our discoveries to patients worldwide.
Our collaborations provide access to additional knowledge, experience, expertise, and human and financial resources. Regeneron has also licensed our human antibody technology to Astellas Pharma and to selected academic institutions for their use in developing additional antibody therapeutics.
Regeneron and Bayer HealthCare
Regeneron and Bayer HealthCare, one of the leading specialty pharmaceutical companies in the world, are collaborating on the global development of EYLEA® (aflibercept) Injection for the treatment of eye disease by local administration. The companies share the costs of development through an integrated global plan. Bayer HealthCare has rights to market EYLEA outside the U.S., where the companies will share equally in profits from future sales. Regeneron may also earn up to $225 million in development and sales milestone payments. Should the collaboration become profitable, Regeneron will reimburse Bayer HealthCare for 50 percent of the development costs that it has incurred under the agreement. Within the U.S., Regeneron retains exclusive commercialization rights to EYLEA and is entitled to all profits from any future sales.
Regeneron and Sanofi
Sanofi is one of the five largest pharmaceutical companies in the world. We initially partnered globally with Aventis, a predecessor company to Sanofi, in 2003 to develop ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion.
In August 2012, ZALTRAP was approved by FDA. Regeneron and Sanofi will share promotion rights and profits from ZALTRAP sales except in Japan, where Regeneron is entitled to receive a royalty of approximately 35 percent of sales. Regeneron may also receive up to $400 million in milestone payments upon receiving specified marketing approvals. Sanofi funds all development expenses incurred by both companies during the term of the agreement. Should the collaboration become profitable, Regeneron will reimburse Sanofi for 50 percent of the development expenses.
ZALTRAP is co-commercialized globally and in the United States with Sanofi. During the initial launch period, Sanofi will be responsible for all field-based promotion and medical affairs activities. In the United States, ZALTRAP is a registered trademark of Regeneron Pharmaceuticals, Inc.
Since 2007, Regeneron has collaborated with Sanofi to discover, develop, manufacture and commercialize fully human monoclonal antibodies utilizing Regeneron's proprietary VelociSuite of technologies. In the first three years of the collaboration, five antibodies entered clinical development.
The collaboration was expanded in 2009 with a goal of advancing 20-30 additional antibodies into clinical development by 2017. Under the terms of the expanded collaboration, Sanofi has agreed to provide $160 million in annual research funding through 2017.
Sanofi has the exclusive option to co-develop each drug candidate in the collaboration portfolio. Development costs are shared between the two companies, with Sanofi funding development costs up front and Regeneron reimbursing half of the development costs from its share of future profits. Although Sanofi will take the lead in commercialization activities, Regeneron will have the right to co-promote all collaboration products worldwide. In the U.S., profits will be shared equally; outside the U.S., profits will be split on a pre-determined sliding scale.